TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: rate of acute GVHD grade II-IV after one year
Endpoint domain: Adverse events/effects
Primary endpoint: Pulse wave signatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in glucose blood level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TSNA Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lifetime alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Past month frequency of any alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Past month frequency of consumption of 4+ (for females) or 5+ (for males) alcoholic drinks at one time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Belinostat
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Grade 3 and 4 Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate (Partial Response (PR) + Complete Response (CR))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: hCAP18 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline 25-OH Vitamin D Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-challenge Diarrhea, Fever, and Blood in Stool Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: duration of supplemental oxygen dependency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difference in intestinal microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Difference in breast milk microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: New or worsening heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of TSPO expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Lequesne index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Womac index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MACCE (Major Adverse Cardiovascular and Cerebrovascular Events)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerability of LBH589
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Number of Accelerometer Intensity Counts Recorded Per Minute During Recess
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Number of Steps Taken Per Minute During Recess
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percentage of Accelerometer Wear Time During Recess Spent in Sedentary Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Spirometry values from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Exhaled Nitric Oxide (FeNO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: cCR rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of bleedings
Endpoint domain: Adverse events/effects
Primary endpoint: Change in SOFA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Administer Influenza Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of relief obtained or success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug deposit amounts in feet nails
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactose malabsorption measured by exhaled hydrogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Perception of Social Media advantages
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perception of Social Media disadvantages
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perception of Social Media use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discomfort of Mammography
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of a Major Adverse Cardiovascular Event
Endpoint domain: Adverse events/effects
Primary endpoint: Scapula-Weighted Constant-Murley Score (SW-CMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operation related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Post operative fever
Endpoint domain: Adverse events/effects
Primary endpoint: Liquor leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Imipenem concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validity of smartphone software for home monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost Effectiveness of VR-JIT
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cumulative incidence of significant GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of fenofibric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of fenofibric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall engagement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Conjunctival hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Symptom Reduction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Waist Circumference at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effect of Obex® on fasting glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical Response and Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Minimal Residual Disease (MRD) Negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pharmacokinetic Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mJOA score change rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean weekly glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Ears Treated Successfully
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of Acute Intraprocedural Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects developing febrile neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Subjects With Grade 3 Solicited and Unsolicited General Reactions After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Administered Doses Eliciting Grade 3 Unsolicited Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Doses Eliciting Solicited Local Symptoms Reported Over 7 Day Follow-up Period
Endpoint domain: Adverse events/effects
Primary endpoint: Ultrasensitive RNA Viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell-associated HIV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specific HIV antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morbidity during perioperation
Endpoint domain: Mortality/survival
Primary endpoint: mortality during perioperation
Endpoint domain: Mortality/survival
Primary endpoint: Change in Myeloproliferative Neoplasm Symptom Assessment Form - Total Symptom Score (MPN-SAF TSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in JAK2 V617F allele burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response to Study Drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Live birth after the first embryo transfer
Endpoint domain: Mortality/survival
Primary endpoint: MTD/RP2D of MLN9708
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of amyloid deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HCV viral load reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Mean Weekly Crying Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cocaine Use by Self-report
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cocaine Use by Urine Benzoylecgonine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with One or More Serious Adverse Event(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive health assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Split renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total Lorazepam Dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative epistaxis
Endpoint domain: Adverse events/effects
Primary endpoint: Post operative rhinoliquorrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Success or failure of the peri-arterial technique injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With a Numeric Rating Scale Score (NRS) of Zero
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intervention acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Content validity of POMAQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cell Viability and Apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell Differentiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Retinal Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatitis B virus (HBV) serological status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area Under the Serum Concentration-Time Curve Over Dosing Interval (AUC14d)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Serum Concentration Obtained From the First Dose (Cmax14d)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Confidence in Decision to be Immunized
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ectopic eruption prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hematology and blood chemistry values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of patients with cancer shrinkage or disappearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Basophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Leukocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Length of Hospital Stay (LOS)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Prevalence of antibody status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ileus incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Wound fluid level of VEGF, VEGFR-2, HIF-1α and NO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV Disease Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New Cognitive Diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Laboratory Investigations Related to Cognitive Impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New Dementia Prescriptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Related Referrals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AzBio Sentence Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Iron Deficiency Anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of increase of Hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Vaccine Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of adverse events, defined as dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Death (all-cause)
Endpoint domain: Mortality/survival
Primary endpoint: Severe HIV-related disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Anxiety in children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety in parents
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of subjects experiencing an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Functional balance and gait with Best Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gait with 6 minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Functional balance with Rapid turn test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Prostate-specific Antigen (PSA) Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite of Number and percent of all treated participants that experience Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of Number and percent of all treated participants that experience serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Blinded Independent Central Review (BICR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Onset of Meaningful Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 14-day Participant Mortality
Endpoint domain: Mortality/survival
Primary endpoint: 29-day Participant Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline ABC-C total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Medication Treatment Modifications (MTM)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dialysis Dependency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Ventilation at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AF free off all Class I and III Anti Arrhythmic Drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of days of hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: dose of analgesia used to control pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of glycoprotein VI collagen receptor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant Primary Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant Secondary Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary acceleration time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in NC function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in cerebral metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in antibiotics and other drugs use during diarrheal illnesses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Increase in ORS use during diarrhea
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in hospitalizations; all cause and diarrhea related
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time Difference Between EEG Cap and Standard EEG Results Reporting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ultrasound parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with laboratory tests findings of potential clinical importance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with clinically significant abnormal ECG QT Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal Concentration (Cmax) of amiodarone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of amiodarone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of amiodarone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Abnormalities Detected by EUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-individual variability of FEV1 z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of acute diarrheal disease
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Amygdala Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Trueness of intaglio surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ERD/ERS amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of Unbound Drug in Plasma (fu)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Study completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain ratings
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Number of participants diagnosed with retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Body Esteem Scale (BES)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Duration of diarrhoeal course
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Surgical condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of HIV Infected Participants Being Virally Suppressed at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of HIV Infected Participants Retained in Care at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid Artery Adventitial Vaso Vasorum Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants Who Could Undergo Partial Nephrectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quantra Fibrinolysis results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes